These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22696224)

  • 1. Developing in vitro-in vivo correlation of risperidone immediate release tablet.
    Saibi Y; Sato H; Tachiki H
    AAPS PharmSciTech; 2012 Sep; 13(3):890-5. PubMed ID: 22696224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®.
    Honório Tda S; Pinto EC; Rocha HV; Esteves VS; dos Santos TC; Castro HC; Rodrigues CR; de Sousa VP; Cabral LM
    AAPS PharmSciTech; 2013 Sep; 14(3):1244-54. PubMed ID: 23943401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique.
    Khames A
    Drug Deliv; 2017 Nov; 24(1):328-338. PubMed ID: 28165818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.
    Yaro P; He X; Liu W; Xun M; Ma Y; Li Z; Shi X
    Drug Dev Ind Pharm; 2014 Dec; 40(12):1670-6. PubMed ID: 24102615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.
    Kovacević I; Parojcić J; Homsek I; Tubić-Grozdanis M; Langguth P
    Mol Pharm; 2009; 6(1):40-7. PubMed ID: 19248231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
    Lake OA; Olling M; Barends DM
    Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications.
    Madny MA; Deshpande P; Tumuluri V; Borde P; Sangana R
    AAPS PharmSciTech; 2022 Apr; 23(4):108. PubMed ID: 35386066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of plasma concentrations using in silico modelling and simulation approach: Case of Acebutolol.
    Bokri E; Felfel H; Bahri S
    Ann Pharm Fr; 2021 Sep; 79(5):530-538. PubMed ID: 33675740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study.
    Shin S; Kim TH; Lee DY; Chung SE; Lee JB; Kim DH; Shin BS
    AAPS J; 2020 Jan; 22(2):27. PubMed ID: 31938935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of Level a In Vitro-In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study.
    Lee DY; Shin S; Kim TH; Shin BS
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.
    Kesisoglou F; Hermans A; Neu C; Yee KL; Palcza J; Miller J
    J Pharm Sci; 2015 Sep; 104(9):2913-22. PubMed ID: 25611455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
    Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
    Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.
    Avramoff A; Domb AJ
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of controlled-release matrix tablet of risperidone: influence of Methocel®- and Ethocel®-based novel polymeric blend on in vitro drug release and bioavailability.
    Badshah A; Subhan F; Rauf K; Bukhari NI; Shah K; Khan S; Ahmed Z; Khan I
    AAPS PharmSciTech; 2011 Jun; 12(2):525-33. PubMed ID: 21494924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.